Although the overall success rates for localized prostate cancer control were high clinically, 20-30% of patients experienced biochemical or clinical recurrence, which initially presented as elevated PSA without specific clinical distant or radiographic metastases. The gene discussed is KLK3; the disease is prostate cancer.